Allergen Specific Sublingual Immunotherapy in Children with Asthma and Allergic Rhinitis

Overview

Journal World J Pediatr

Specialty Pediatrics

Date 2016 Jun 29

PMID 27351563

Citations 11

Authors

Ivana duric-Filipovic

Marco Caminati

Gordana Kostic

dorde Filipovic

Zorica ZivkoviC

Affiliations

Soon will be listed here.

Abstract

Background: The incidence of asthma and allergic rhinitis (AR) is significantly increased, especially in younger children. Current treatment for children with asthma and allergic rhinitis include allergen avoidance, standard pharmacotherapy, and immunotherapy. Since standard pharmacotherapy is prescribed for symptoms, immunotherapy at present plays an important role in the treatment of allergic diseases. This article presents insights into the up-to-date understanding of immunotherapy in the treatment of children with allergic rhinitis and asthma.

Data Sources: PubMed articles published from 1990 to 2014 were reviewed using the MeSH terms "asthma", "allergic rhinitis", "children", and "immune therapy". Additional articles were identified by hand searching of the references in the initial search.

Results: Numerous studies have shown that sublingual application of allergen specific immunotherapy (SLIT) is an adequate, safe and efficient substitution to subcutaneous route of allergens administration (SCIT) in the treatment of IgE-mediated respiratory tract allergies in children. According to the literature, better clinical efficacy is connected with the duration of treatment and mono sensitized patients.

Conclusions: At least 3 years of treatment and stable asthma before the immunotherapy are positive predictors of good clinical efficacy and tolerability of SLIT. SLIT reduces the symptoms of allergic diseases and the use of medicaments, and improves the quality of life of children with the diseases.

Citing Articles

Immunotherapy in the Treatment of Allergic Rhinitis in Children.

Alamri R, Aljabri G, Tahlawi R, Aljabri H Cureus. 2023; 14(12):e32464.

PMID: 36644088 PMC: 9834958. DOI: 10.7759/cureus.32464.

Diagnosis and Management of Allergic Rhinitis in Asthmatic Children.

Tenero L, Vaia R, Ferrante G, Maule M, Venditto L, Piacentini G J Asthma Allergy. 2023; 16:45-57.

PMID: 36636703 PMC: 9829985. DOI: 10.2147/JAA.S281439.

Do not forget asthma comorbidities in pediatric severe asthma!.

Ronco L, Folino A, Goia M, Crida B, Esposito I, Bignamini E Front Pediatr. 2022; 10:932366.

PMID: 35967579 PMC: 9372496. DOI: 10.3389/fped.2022.932366.

Effect of Traditional Chinese Medicine on Allergic Rhinitis in Children under Data Mining.

Shen M, Liu J, Wang K Comput Math Methods Med. 2022; 2022:7007370.

PMID: 35693255 PMC: 9177320. DOI: 10.1155/2022/7007370.

Serum vitamin D level in mice with allergic rhinitis is correlated with inflammatory factors.

Fang X, Xie Q, Zhang X Am J Transl Res. 2021; 13(4):3351-3356.

PMID: 34017509 PMC: 8129401.

References

Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner D . Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol. 2011; 127(1):64-71, 71.e1-4. DOI: 10.1016/j.jaci.2010.11.034. View

Frew A, Powell R, Corrigan C, Durham S . Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006; 117(2):319-25. DOI: 10.1016/j.jaci.2005.11.014. View

Didier A, Malling H, Worm M, Horak F, Jager S, Montagut A . Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007; 120(6):1338-45. DOI: 10.1016/j.jaci.2007.07.046. View

Dahl R, Kapp A, Colombo G, de Monchy J, Rak S, Emminger W . Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol. 2007; 121(2):512-518.e2. DOI: 10.1016/j.jaci.2007.10.039. View

Passalacqua G, Canonica G . Specific immunotherapy in asthma: efficacy and safety. Clin Exp Allergy. 2011; 41(9):1247-55. DOI: 10.1111/j.1365-2222.2010.03688.x. View

Tari M, Mancino M, Monti G . Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr). 1990; 18(5):277-84. View

Zhang L, Zhao Y . The regulation of Foxp3 expression in regulatory CD4(+)CD25(+)T cells: multiple pathways on the road. J Cell Physiol. 2007; 211(3):590-7. DOI: 10.1002/jcp.21001. View

Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L . Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol. 2009; 123(1):167-173.e7. DOI: 10.1016/j.jaci.2008.10.044. View

Bufe A, Ziegler-Kirbach E, Stoeckmann E, Heidemann P, Gehlhar K, Holland-Letz T . Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy. 2004; 59(5):498-504. DOI: 10.1111/j.1398-9995.2004.00457.x. View

10.

Mantel P, Kuipers H, Boyman O, Rhyner C, Ouaked N, Ruckert B . GATA3-driven Th2 responses inhibit TGF-beta1-induced FOXP3 expression and the formation of regulatory T cells. PLoS Biol. 2007; 5(12):e329. PMC: 2222968. DOI: 10.1371/journal.pbio.0050329. View

11.

Juniper E, Guyatt G . Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991; 21(1):77-83. DOI: 10.1111/j.1365-2222.1991.tb00807.x. View

12.

Lin S, Erekosima N, Kim J, Ramanathan M, Suarez-Cuervo C, Chelladurai Y . Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA. 2013; 309(12):1278-88. DOI: 10.1001/jama.2013.2049. View

13.

Pham-Thi N, Scheinmann P, Fadel R, Combebias A, Andre C . Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol. 2007; 18(1):47-57. DOI: 10.1111/j.1399-3038.2006.00475.x. View

14.

Pajno G, Caminiti L, Crisafulli G, Barberi S, Landi M, Aversa T . Adherence to sublingual immunotherapy in preschool children. Pediatr Allergy Immunol. 2012; 23(7):688-9. DOI: 10.1111/j.1399-3038.2012.01317.x. View

15.

Ozdemir C, Yazi D, Gocmen I, Yesil O, Aydogan M, Semic-Jusufagic A . Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma. Pediatr Allergy Immunol. 2007; 18(6):508-15. DOI: 10.1111/j.1399-3038.2007.00549.x. View

16.

Bahceciler N, Isik U, Barlan I, Basaran M . Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol. 2001; 32(1):49-55. DOI: 10.1002/ppul.1088. View

17.

Marcucci F, Sensi L, Di Cara G, Incorvaia C, Frati F . Dose dependence of immunological response to sublingual immunotherapy. Allergy. 2005; 60(7):952-6. DOI: 10.1111/j.1398-9995.2005.00786.x. View

18.

Fenoglio D, Puppo F, Cirillo I, Vizzaccaro A, Ferrera A, Tosca M . Sublingual specific immunotherapy reduces PBMC proliferations. Eur Ann Allergy Clin Immunol. 2005; 37(4):147-51. View

19.

Bachert C, Canonica G, Bufe A . SIT: efficacy depends on product, not on route of application. Pediatr Allergy Immunol. 2012; 23(4):401. DOI: 10.1111/j.1399-3038.2012.01285.x. View

20.

Yukselen A, Guneser Kendirli S, Yilmaz M, Altintas D, Karakoc G . Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. Int Arch Allergy Immunol. 2011; 157(3):288-98. DOI: 10.1159/000327566. View